Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SHFS vs LGND vs PRGO vs INVA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SHFS
SHF Holdings, Inc.

Banks - Regional

Financial ServicesNASDAQ • US
Market Cap$1M
5Y Perf.-99.8%
LGND
Ligand Pharmaceuticals Incorporated

Biotechnology

HealthcareNASDAQ • US
Market Cap$4.13B
5Y Perf.+59.0%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-71.4%
INVA
Innoviva, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.93B
5Y Perf.+49.4%

SHFS vs LGND vs PRGO vs INVA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SHFS logoSHFS
LGND logoLGND
PRGO logoPRGO
INVA logoINVA
IndustryBanks - RegionalBiotechnologyDrug Manufacturers - Specialty & GenericBiotechnology
Market Cap$1M$4.13B$1.61B$1.93B
Revenue (TTM)$18M$251M$4.18B$424M
Net Income (TTM)$-53M$49M$-1.82B$504M
Gross Margin104.7%85.9%34.2%76.2%
Operating Margin-24.2%7.0%-4.1%14.8%
Forward P/E23.6x5.6x11.9x
Total Debt$12M$7M$3.97B$269M
Cash & Equiv.$2M$72M$532M$551M

SHFS vs LGND vs PRGO vs INVALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SHFS
LGND
PRGO
INVA
StockAug 21May 26Return
SHF Holdings, Inc. (SHFS)1000.2-99.8%
Ligand Pharmaceutic… (LGND)100159.0+59.0%
Perrigo Company plc (PRGO)10028.6-71.4%
Innoviva, Inc. (INVA)100149.4+49.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: SHFS vs LGND vs PRGO vs INVA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INVA leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Ligand Pharmaceuticals Incorporated is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. PRGO also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SHFS
SHF Holdings, Inc.
The Financial Play

SHFS lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: financial services exposure
LGND
Ligand Pharmaceuticals Incorporated
The Growth Leader

LGND is the #2 pick in this set and the best alternative if growth and momentum is your priority.

  • 27.3% revenue growth vs SHFS's -9.2%
  • +99.1% vs SHFS's -81.8%
Best for: growth and momentum
PRGO
Perrigo Company plc
The Income Pick

PRGO is the clearest fit if your priority is income & stability.

  • Dividend streak 10 yrs, beta 1.18, yield 9.8%
  • Lower P/E (5.6x vs 11.9x)
  • 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Best for: income & stability
INVA
Innoviva, Inc.
The Growth Play

INVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
  • 94.9% 10Y total return vs LGND's 73.0%
  • Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
  • Beta 0.13, current ratio 14.64x
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthLGND logoLGND27.3% revenue growth vs SHFS's -9.2%
ValuePRGO logoPRGOLower P/E (5.6x vs 11.9x)
Quality / MarginsINVA logoINVA118.9% margin vs SHFS's -262.5%
Stability / SafetyINVA logoINVABeta 0.13 vs SHFS's 1.87
DividendsPRGO logoPRGO9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)LGND logoLGND+99.1% vs SHFS's -81.8%
Efficiency (ROA)INVA logoINVA32.4% ROA vs SHFS's -389.6%, ROIC 14.2% vs -13.7%

SHFS vs LGND vs PRGO vs INVA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SHFSSHF Holdings, Inc.

Segment breakdown not available.

LGNDLigand Pharmaceuticals Incorporated
FY 2024
Royalty
27.9%$109M
Intangible Royalty Assets
24.4%$95M
Royalty, Kyprolis
9.8%$38M
Material Sales, Captisol, Core
7.9%$31M
Material Sales, Captisol
7.9%$31M
Contract Revenue
7.0%$27M
Service
6.5%$26M
Other (4)
8.5%$33M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
INVAInnoviva, Inc.
FY 2025
Royalty
57.5%$236M
Product
41.8%$172M
License And Other Revenue
0.7%$3M

SHFS vs LGND vs PRGO vs INVA — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINVALAGGINGLGND

Income & Cash Flow (Last 12 Months)

INVA leads this category, winning 3 of 6 comparable metrics.

PRGO is the larger business by revenue, generating $4.2B annually — 227.0x SHFS's $18M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to SHFS's -2.6%. On growth, LGND holds the edge at +122.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
RevenueTrailing 12 months$18M$251M$4.2B$424M
EBITDAEarnings before interest/tax-$11M$52M$58M$86M
Net IncomeAfter-tax profit-$53M$49M-$1.8B$504M
Free Cash FlowCash after capex-$5M$31M$108M$181M
Gross MarginGross profit ÷ Revenue+104.7%+85.9%+34.2%+76.2%
Operating MarginEBIT ÷ Revenue-24.2%+7.0%-4.1%+14.8%
Net MarginNet income ÷ Revenue-2.6%+19.3%-43.5%+118.9%
FCF MarginFCF ÷ Revenue+2.3%+12.2%+2.6%+42.8%
Rev. Growth (YoY)Latest quarter vs prior year+122.8%-7.2%+10.6%
EPS Growth (YoY)Latest quarter vs prior year-53.8%+15.6%-56.4%+4.0%
INVA leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 3 of 6 comparable metrics.

On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than LGND's 322.1x.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
Market CapShares × price$1M$4.1B$1.6B$1.9B
Enterprise ValueMkt cap + debt − cash$11M$4.1B$5.1B$1.7B
Trailing P/EPrice ÷ TTM EPS-0.03x-956.05x-1.14x6.91x
Forward P/EPrice ÷ next-FY EPS est.23.65x5.56x11.91x
PEG RatioP/E ÷ EPS growth rate0.67x
EV / EBITDAEnterprise value multiple322.10x7.42x8.10x
Price / SalesMarket cap ÷ Revenue0.07x24.74x0.38x4.55x
Price / BookPrice ÷ Book value/share4.63x0.55x1.65x
Price / FCFMarket cap ÷ FCF3.15x53.41x11.12x9.88x
PRGO leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

INVA leads this category, winning 7 of 9 comparable metrics.

INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-8 for SHFS. LGND carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), LGND scores 5/9 vs PRGO's 4/9, reflecting solid financial health.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
ROE (TTM)Return on equity-7.6%+5.1%-50.7%+46.5%
ROA (TTM)Return on assets-3.9%+3.3%-19.8%+32.4%
ROICReturn on invested capital-13.7%-2.3%+3.7%+14.2%
ROCEReturn on capital employed-13.1%-2.7%+4.3%+12.4%
Piotroski ScoreFundamental quality 0–94545
Debt / EquityFinancial leverage0.01x1.35x0.23x
Net DebtTotal debt minus cash$10M-$65M$3.4B-$282M
Cash & Equiv.Liquid assets$2M$72M$532M$551M
Total DebtShort + long-term debt$12M$7M$4.0B$269M
Interest CoverageEBIT ÷ Interest expense-17.46x22.69x-7.20x63.45x
INVA leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — LGND and INVA each lead in 3 of 6 comparable metrics.

A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $24 for SHFS. Over the past 12 months, LGND leads with a +99.1% total return vs SHFS's -81.8%. The 3-year compound annual growth rate (CAGR) favors LGND at 39.5% vs SHFS's -64.1% — a key indicator of consistent wealth creation.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
YTD ReturnYear-to-date-55.3%+10.6%-13.5%+14.7%
1-Year ReturnPast 12 months-81.8%+99.1%-51.2%+21.7%
3-Year ReturnCumulative with dividends-95.4%+171.6%-58.1%+95.2%
5-Year ReturnCumulative with dividends-99.8%+61.0%-60.1%+94.4%
10-Year ReturnCumulative with dividends-99.8%+73.0%-77.7%+94.9%
CAGR (3Y)Annualised 3-year return-64.1%+39.5%-25.2%+25.0%
Evenly matched — LGND and INVA each lead in 3 of 6 comparable metrics.

Risk & Volatility

INVA leads this category, winning 2 of 2 comparable metrics.

INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than SHFS's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 90.7% from its 52-week high vs SHFS's 5.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
Beta (5Y)Sensitivity to S&P 5001.87x0.99x1.18x0.13x
52-Week HighHighest price in past year$9.19$247.38$28.44$25.15
52-Week LowLowest price in past year$0.38$98.89$9.23$16.52
% of 52W HighCurrent price vs 52-week peak+5.1%+85.0%+41.2%+90.7%
RSI (14)Momentum oscillator 0–10045.459.360.939.9
Avg Volume (50D)Average daily shares traded270K226K3.4M621K
INVA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

PRGO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: LGND as "Buy", PRGO as "Hold", INVA as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 27.3% for LGND (target: $268). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.

MetricSHFS logoSHFSSHF Holdings, Inc.LGND logoLGNDLigand Pharmaceut…PRGO logoPRGOPerrigo Company p…INVA logoINVAInnoviva, Inc.
Analyst RatingConsensus buy/hold/sellBuyHoldBuy
Price TargetConsensus 12-month target$267.75$20.00$37.67
# AnalystsCovering analysts173610
Dividend YieldAnnual dividend ÷ price+9.8%
Dividend StreakConsecutive years of raises1100
Dividend / ShareAnnual DPS$1.15
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+0.2%
PRGO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

INVA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallInnoviva, Inc. (INVA)Leads 3 of 6 categories
Loading custom metrics...

SHFS vs LGND vs PRGO vs INVA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SHFS or LGND or PRGO or INVA a better buy right now?

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus -9. 2% for SHF Holdings, Inc. (SHFS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SHFS or LGND or PRGO or INVA?

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — SHFS or LGND or PRGO or INVA?

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -99. 8% for SHF Holdings, Inc. (SHFS). Over 10 years, the gap is even starker: INVA returned +94. 9% versus SHFS's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SHFS or LGND or PRGO or INVA?

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus SHF Holdings, Inc. 's 1. 87β — meaning SHFS is approximately 1385% more volatile than INVA relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — SHFS or LGND or PRGO or INVA?

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus -9. 2% for SHF Holdings, Inc. (SHFS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, INVA leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SHFS or LGND or PRGO or INVA?

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -262. 5% for SHF Holdings, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -24. 2% for SHFS. At the gross margin level — before operating expenses — SHFS leads at 104. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SHFS or LGND or PRGO or INVA more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 23. 6x for Ligand Pharmaceuticals Incorporated — 18. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — SHFS or LGND or PRGO or INVA?

In this comparison, PRGO (9.

8% yield) pays a dividend. SHFS, LGND, INVA do not pay a meaningful dividend and should not be held primarily for income.

09

Is SHFS or LGND or PRGO or INVA better for a retirement portfolio?

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). SHF Holdings, Inc. (SHFS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, SHFS: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SHFS and LGND and PRGO and INVA?

These companies operate in different sectors (SHFS (Financial Services) and LGND (Healthcare) and PRGO (Healthcare) and INVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SHFS is a small-cap quality compounder stock; LGND is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; INVA is a small-cap high-growth stock. PRGO pays a dividend while SHFS, LGND, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SHFS

Quality Business

  • Sector: Financial Services
  • Market Cap > $100B
  • Gross Margin > 62%
Run This Screen
Stocks Like

LGND

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 61%
  • Net Margin > 11%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

INVA

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 71%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SHFS and LGND and PRGO and INVA on the metrics below

Revenue Growth>
%
(SHFS: -9.2% · LGND: 122.8%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.